Relapse after allogeneic hematopoietic SCT (HSCT) carries a poor prognosis and is a common cause of death. Outcomes of children who relapse post HSCT are not well known. In this retrospective multicenter study we included 532 patients who underwent allogeneic HSCT and examined the outcomes of 160 patients (30%) who relapsed. Treatment options after relapse included (i) palliative therapy with non-curative intent (n ¼ 43), (ii) salvage chemotherapy (without a second HSCT, n ¼ 55) or (iii) salvage chemotherapy followed by a second HSCT (n ¼ 62). Sixty two patients underwent a second HSCT. The 1-year disease-free survival (DFS) for those given palliative therapy, chemotherapy alone and who underwent a second transplant was o1%, 9% and 50% (P ¼ o0.0001), respectively. The DFS at 1 and 2 year was 50% and 35%, respectively, among the patients who received a second transplant versus 9% and 2% in those who did not (P ¼ o0.0001). In multivariable analysis longer time to relapse (P ¼ 0.04) and undergoing a second HSCT (Po0.001) were associated with improved outcome. Withdrawal of immunosuppressive therapy, followed by curative intent chemotherapy should be offered to all patients who relapse after an allogeneic HSCT. A second HSCT should be considered, especially in patients who respond to salvage chemotherapy. 1 In the recent European Bone Marrow transplantation report on behalf of the acute leukemia working party, the 5-year OS was 8 ± 1% for adults who experience relapse post-transplant.
INTRODUCTION
Relapse of the primary malignancy after HSCT is a common cause of transplant failure. According to the Center for International Blood and Marrow Transplantation and Research data, relapse accounts for 41% of deaths after matched-sibling donor HSCT and 34% of deaths after unrelated-donor HSCT. 1 In the recent European Bone Marrow transplantation report on behalf of the acute leukemia working party, the 5-year OS was 8 ± 1% for adults who experience relapse post-transplant. 2 Similarly, patients who experience relapse after reduced intensity conditioning (RIC) HSCT, have a 2-year OS of 29%. 3 Second allogeneic HSCT has always been considered a potential treatment option for patients who relapse following their first transplant. In a retrospective study of 150 adult patients who underwent a second HSCT, the reported 5-year OS and disease-free survival (DFS) were 32% and 30%, respectively; the risks of relapse and a non-relapse mortality (NRM) were 44% and 45%, respectively. 4 Kurosawa et al. 5 from Japan reported that the 1-year OS after post-transplant relapse was significantly better at 58% in patients who had a second HSCT as compared with 14% in the cohorts who got chemotherapy or no intervention with curative intent. They concluded that for patients who relapse after transplant, successful re-induction chemotherapy and a second HSCT may be effective for prolonging survival without excessive NRM. While the overall prognosis of patients relapsing after a RIC HSCT is poor, interventions such as the combined use of immunotherapy and chemotherapy can improve patient survival. Patients who relapse after a RIC HSCT and receive subsequent therapy had a better outcome than those who did not receive any intervention. 6 Most published pediatric studies focus on the outcome from the first or second transplant and there are very limited data on outcome from the time of relapse following the first allogeneic HSCT. There are no established standard treatment guidelines for these patients and treatment varies among institutions. We report on the outcome of 160 patients who relapsed following allogeneic HSCT from five pediatric transplant programs in North America. We sought to evaluate the outcome of these patients and the effect of a second allogeneic HSCT.
METHODS
For this multicenter, retrospective study, patients with primary diagnoses of ALL, AML or CML, juvenile myelomonocytic leukemia, secondary AML, acute biphenotypic leukemia, acute undifferentiated leukemia and myelodysplastic syndrome (MDS) were included. The study was approved by the Institutional review boards of all five participating centers. The transplant database at each center contains prospectively collected detailed data on all patients transplanted. All patients with hematological malignancies undergoing HSCT at each institution were included in the study. For patients who experienced relapse of primary disease, all available medical records, were reviewed to identify, in detail, the site of relapse, salvage therapy, second allogeneic HSCT and outcome.
Definitions
Relapse after HSCT was defined as the presence of 45% blasts as detected by morphology on BM. Detection of minimal residual disease or molecular relapse without morphological abnormalities in the BM did not qualify as a relapse. CR was defined as normocellular BM with o5% blasts along with the absence of blasts in peripheral blood. Biopsy or cerebrospinal fluid examination was essential for the diagnosis of isolated extramedullary relapse. Partial response was defined as a decrease in the blast count by at least 50% in the BM from diagnosis, but not meeting the definition of CR. Survival after relapse was measured from the date of relapse to the time of death or censored to the date of last contact. DFS includes all surviving patients without evidence of disease. NRM was defined as death from causes other than relapse/recurrence of primary disease. Interventions after the diagnosis of relapse included, (i) withdrawal of immuno-suppression defined as cessation of all immunosuppressive medications, (ii) palliative therapy or (iii) salvage therapy (with curative intent). Salvage therapies included, (i) DLI, (ii) chemotherapy only (without a second HSCT) and (iii) chemotherapy followed by a second HSCT (from the same or other donor).
Statistical analysis
The primary objective of the study was to define the outcome of patients who experience relapse after an allogeneic HSCT for hematological malignancies in children. Secondary objectives included: (i) To find the treatment options for patients who experienced a disease relapse after allogeneic HSCT and (ii) To find the DFS after relapse of primary disease. We also compared the outcomes of patients who underwent a second HSCT, with those who did not undergo a second HSCT after salvage therapy for post-transplant relapse and were treated with chemotherapy only. Data were retrospectively reviewed and analyzed. Summary statistics were used to summarize all variables. For continuous variables, mean and s.d. were provided. For categorical variables, frequency was provided. w 2 -test or Fisher's exact test was used for categorical data comparison. DFS was estimated by the Kaplan-Meier method. The log-rank test was used to compare the probabilities of survival over time across patient subgroups. We considered two-sided P-values of o0.05 to be statistically significant. Statistical analyses were performed with the SAS version 9.2 (SAS, Cary, NC, USA).
RESULTS
From 1992 to Dec 2010, 532 patients underwent allogeneic HSCT for a hematological malignancy at five institutions across North America and their data were analyzed for this report. Detailed patient characteristics are presented in Table 1 . The median age at HSCT was 9.7 years (range 0.44-25). At the time of first HSCT, 84% of the patients were in CR, 4% had chronic phase CML, 5% were refractory to treatment and 7% had MDS. Myeloablative conditioning was used for 97% patients and 3% had a RIC HSCT. TBI containing regimens were used in 63% of the cases and 37% of the patients received non-TBI, chemotherapy-based regimens. GVHD prophylaxis with CYA or tacrolimus þ MTX was the most commonly used regimen. Thirty-one percent, 43%, 10% and 4% of patients received HLA matched-related donor, matched-unrelated donor, mismatched-unrelated donor, mismatched-related donor transplants and the details of the HLA matching and related/ unrelated status was unknown in the remaining 12% of the patients. BM, PBSCs, and umbilical cord blood were the source of stem cells in 71%, 13% and 16% of the transplants, respectively. None of the patients received T-cell-depleted grafts. Six patients had primary graft failure after the first transplant, then underwent a second HSCT and all died; these patients were excluded from further analysis. The cumulative incidence of grade 1-2 and grade 3-4 acute GVHD was 32.5% and 15%, respectively. The cumulative incidence of limited and extensive chronic GVHD was 11% each. NRM was the cause of death for 107 (20%) patients, who died at a median time of 3 months (range 0.4-84) after the first HSCT; 80 of these 107 deaths (75%) were within the first 12 months after HSCT.
One hundred and sixty patients (30%) relapsed within a median of 7 months (range 0.33-66 months) post HSCT, with 108 (66%) patients experiencing relapse within 12 months post-HSCT. Thirtyone percent each of the ALL and AML, 23% of CML, and 17% of MDS patients relapsed post-HSCT. One of the three with acute undifferentiated leukemia, 4 of the 10 acute biphenotypic leukemia and two of the three with juvenile myelomonocytic leukemia patients also relapsed.
The summary of interventions and outcome of patients who relapsed post-HSCT is depicted in Figure 1 . All patients who relapsed after transplant were weaned off any immunosuppressive therapy being given at that point. Palliative treatment was given to 43 (27%) patients and they all died at a median of 1 month (range 0.1-11) after relapse. One hundred and seventeen patients (73%) received salvage therapy. Over 25 different types of salvage therapy were used across the five institutions for patients who relapsed post transplant. Salvage therapies included a combination of withdrawal of immunosuppression, DLI, ALL or AML induction therapy (n ¼ 43), or other chemotherapy agents (n ¼ 35). The details of salvage chemotherapy were not known in 39 patients. DLI DLI was given to 20 patients after withdrawal of immunosuppression, 4 (20%) patients are alive; 3 patients after getting further chemotherapy followed by a second HSCT, and 1 patient with MDS who received salvage chemotherapy followed by DLI, but no second HSCT.
After salvage chemotherapy, 54 (46%) patients achieved CR, 38 (32.5%) had no response, 3 (2.5%) had partial response, 4 (3.4%) Relapse after SCT in children R Bajwa et al had aplasia and in 18 (15.4%) the response to salvage chemotherapy was not known. After salvage chemotherapy, 62 patients (47 with CR, 6 with no response, 2 with aplasia and 7 with unknown disease status) received a second HSCT whereas 55 patients (7 with CR, 32 with no response, 3 with partial response, 2 with aplasia and 11 with unknown disease status) did not receive a second transplant. Fifty-five (47%) patients received salvage chemotherapy only and did not undergo a second HSCT; 53/55 (96%) patients died within a median duration of 2 months (range 0.2-25) after post-HSCT relapse; relapse was the cause of death in 42 patients and 11 died from non-relapse causes (infection n ¼ 6, graft failure and respiratory failure 1 each and unknown n ¼ 3). Only 2 of these 55 (4%) patients are alive: a patient with MDS who received salvage chemotherapy followed by DLI (mentioned above) and another patient with ALL, who had isolated testicular relapse, underwent orchiectomy and received local irradiation.
A total of 62 patients underwent a second HSCT after posttransplant relapse. We compared the group of patients who received salvage chemotherapy, but no second transplant (n ¼ 55), with those who received chemotherapy followed by a second HSCT (n ¼ 62) ( Table 2 ). There was no difference in age, disease type, donor typed or conditioning regimen received for the first HSCT. Patients who underwent a second transplant had relapsed at a median of 10.5 months (range 0.3-43) compared with 5 months (range 1-50) for those who did not undergo a second HSCT (Po0.001). For the second HSCT BU-, fludarabineand clofarabine-based regimens were used for 11, 18 and 1 patient, respectively. The median time interval between the first and second HSCT was 13 months (range 1-53). BM, PBSCs and umbilical cord blood were the stem cell source for the 20 (32%), 34 (55%), and 8 (13%) of the patients, respectively. The same donor (as for the first HSCT) was used for 39 (63%) of the transplants and another donor was found in the remaining 23 (37%). After the second transplant, 43 (69%) of the patients died; 24% from non-relapse causes and the remaining from relapse of primary disease. Patients with NRM died at a median of 2 months (range 0.36-17) from infection (n ¼ 5), multi-organ failure (n ¼ 3), aGVHD, veno-occlusive disease, respiratory failure, cardiac toxicity and unknown, one each, and two from regimen-related toxicity. Patients who relapsed after the second HSCT, did so at a median time of 5.5 months (range 0.9-51), 19 (68%) of the 28 relapses were within 12 months after the second HSCT, and 23 (82%) within 24 months. All patients who experienced relapse after the second transplant died. After the second transplant 19/62 (31%) patients are alive and in CR (ALL ¼ 7, AML ¼ 6, MDS ¼ 2, CML ¼ 1, acute biphenotypic leukemia ¼ 2, acute undifferentiated leukemia ¼ 1). The median follow up of surviving patients is 32 months (range 4-183). The DFS at 1 and 2 years for those receiving a second allogeneic HSCT is 50% and 35%, respectively. There was no significant difference in relapse, transplant-related mortality or survival among those receiving fully ablative versus RIC HSCT, although the numbers are small. When comparing patients who experienced relapse after HSCT, there was a trend towards less relapse after second allogeneic HSCT compared with those receiving only salvage chemotherapy (P ¼ 0.08). The DFS at 1 and 2 year was 50% and 35%, respectively, among the patients who received a second transplant versus 9% and 2%, respectively, in those who did not undergo a second transplant (Figure 2 ). Relapse after SCT in children R Bajwa et al
Overall, 21/117 (18%) patients who were given curative intent salvage therapy survived, 2 with chemotherapy only and 19 (16%) after undergoing a second HSCT. Table 3 shows the univariate analysis of various factors associated with 2-year survival after relapse following the first transplant. Improved survival was observed in patients who relapsed 412 months after the first transplant (P ¼ 0.0218) and in those who underwent a second transplant (Po0.0001). Among those relapsing o12 months after the first transplant, 8/39 (20%) patients are alive after undergoing a second HSCT. On further analysis of those relapsing within 12 months of the first transplant, 0/3, 3/3, 0/5, 0/16, and 5/12 patients are alive following a second transplant, after relapsing between 0-1, 1-3, 4-6, 7-9 and 10-12 months of an initial transplant, respectively. Thus all 3 patients who relapsed between 1 and 3 months after an initial transplant survived after undergoing a second HSCT, however there were no survivors among the 21 patients who relapsed between 4 and 9 months and then had a second HSCT. Further 5 of the 12 patients who relapsed between 10 and 12 months after an initial HSCT are alive after a second HSCT. In a multivariate analysis model both time to relapse (relative risk ¼ 0.97, 95% confidence interval: 0.95-0.99, P ¼ 0.04) and undergoing a second HSCT (hazard ratio ¼ 0.31, 95% confidence interval: 0.2-0.48, Po0.001) was associated with improved survival.
After the second HSCT, 27 (44%) patients had no acute GVHD, 32 (52%) had grade 1-4 acute GVHD, while no information was available for 3 (5%) patients. Grade 1-2 acute GVHD was seen in 24 (39%) and grade 3-4 GVHD was seen in 8(13%) patients. After the second HSCT, chronic GVHD was seen in 12 (19%), 40 (65%) had no evidence of chronic GVHD and no information was available in the remaining 10 (16%) patients. Chronic GVHD was mild, moderate or severe in 6 (10%), 2(3%) and 4(6%) patients, respectively. DISCUSSION Despite significant improvement in supportive care and donor selection, which decreased NRM following HSCT, very little progress has been made to decrease the risk of relapse. Relapse continues to be one of the main causes of failure following allogeneic HSCT for malignant diseases. 7 Although one in three children will likely relapse following HSCT, physicians are left with no clear data to guide their management of those patients. Several studies have evaluated the outcome of patients with hematologic malignancies who relapse following allogeneic HSCT. 2, 3, 5, 6, 8 The majority of those studies include only adult patients or very limited pediatric patients. The Seattle group reported on the outcomes of 307 adult patients who relapsed following HSCT; the 2-year survival was 3-19% depending on the time from transplant to relapse with those experiencing relapse 4200 days having the best outcome. 8 In this study, interventions did not include a second transplant. The European Bone Marrow Transplantation organization reported on the outcomes of 465 adult patients with ALL and the 5-year OS was 1%. 2 Kurosawa et al. 5 reported on 93 adult patients with hematologic malignancies who relapsed following allogeneic HSCT. Sixty-three patients underwent re-induction therapy and 27 (43%) achieved a CR. Although the 1-year survival of those receiving a second transplant was better than in those who did not, 51% versus 14%; the 2-year survival was not different. Similar results were observed in patients who experienced relapse following RIC. 3, 6 Our study is the first to evaluate the outcome of children with hematologic malignancies who relapse following allogeneic HSCT. Most prior studies either include no children or focused on the outcome following a second allogeneic HSCT. 4, 9, 10 There were no patients surviving for 41 year after palliative therapy in our study. The reason for not receiving any additional therapy is not clear from our review of the records. We can only speculate about the decision making process of the treating physicians. One hundred and seventeen patients received salvage therapy and interestingly among the 78 patients with available details of re-induction therapy, 25 different regimens were used. The number of regimens used in those patients underscores the lack of uniform therapy for children who relapse following allogeneic HSCT. Unlike what has been observed in adult patients, pediatric patients who received a second HSCT had a significantly improved survival compared with those who were treated with salvage chemotherapy alone (35% versus 2%). It is also clear from our data that there is no consistent approach regarding the preparative regimen, intensity or timing of the second HSCT. A report from the Center for International Blood and Marrow Transplantation and Research on the outcome following second allogeneic HSCT in patients with acute and chronic leukemia found that patients younger than 20 years and those who relapse 46 months from the first HSCT have improved survival. 9 Similarly, the French study on 150 patients (including children) receiving a second allogeneic HSCT, reported that patients o16 years of age and those experiencing relapse more than 12 month from first transplant had improved OS. 4 The main limitation of those studies is that they report on outcome from the time of second HSCT. In our study, only 62 of 160 (39%) patients underwent a second allogeneic HSCT. Our study shows that time to relapse of 412 months and receiving a second transplant were the only significant factors influencing overall outcome. However 20% of our patients, who relapsed within a year of the first transplant, are alive after a second HSCT (3 of these had relapsed within 3 months of the first transplant). None of the patients who relapsed within 1 month of the first transplant and underwent a second HSCT are alive. Because of the small numbers, we are in no position to define a cut off time for not offering a second transplant especially if the patient is in CR after salvage chemotherapy. Despite undergoing a second transplant 45% of the patients experienced relapsed disease post transplant. This might be related to the fact that some patients might have residual or refractory disease at the time of the second transplant. The NRM following the second transplant was 24%, which is relatively comparable to the 20% following the first transplant. Additional prospective studies should be aimed to defining the risk factors for relapse and reducing relapse following the second HSCT.
Our study has several limitations, most importantly the data were collected retrospectively and it is hard to know why some patients received, while others did not receive salvage chemotherapy with or without a second HSCT. Missing data, relating to the types of salvage chemotherapy and rationale for choosing palliative therapy or curative intent therapy (including second HSCT), are missing and are limitations of our study. We presume that physician's bias of offering a second HSCT to patients who would tolerate the therapy or had a better chance of survival might have also affected the outcome. Unknown salvage therapy and other transplant variables maybe the other factors affecting outcome. That the second HSCT group had more patients with CR status than those given chemotherapy, only maybe another limitation of a retrospective study.
The lack of standardized therapy for children with hematologic disease, who experience relapse as highlighted in our study, is very concerning. Most children who experience post-HSCT relapse are not eligible for cooperative group studies and are excluded from many studies of novel therapeutic agents. This is especially true in patients who relapse early following transplant and are still receiving immuno-suppressive therapy. There is an urgent need to develop multicenter clinical trials to address this underserved, but yet, substantial number of patients. Despite the eventual biases in such retrospective studies related to selection of the best treatment of patients who relapse after a first HSCT, our study shows that, withdrawal of immunosuppression followed by curative intent salvage chemotherapy should be considered for most relapsed patients. Further, a second transplant might offer a potential curative option and should be considered, especially if the patients respond to salvage chemotherapy.
